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ABSTRACT
Genogroup II, genotype 4 (GII.4) noroviruses are known to rapidly evolve, with the emergence of a new primary strain every 2 to
4 years as herd immunity to the previously circulating strain is overcome. Because viral genetic diversity is higher in chronic
than in acute infection, chronically infected immunocompromised people have been hypothesized to be a potential source for
new epidemic GII.4 strains. However, while some capsid protein residues are under positive selection and undergo patterned
changes in sequence variation over time, the relationships between genetic variation and antigenic variation remains unknown.
Based on previously published GII.4 strains from a chronically infected individual, we synthetically reconstructed virus-like par-
ticles (VLPs) representing early and late isolates from a small-bowel transplant patient chronically infected with norovirus, as
well as the parental GII.4-2006b strain. We demonstrate that intrahost GII.4 evolution results in the emergence of antigenically
distinct strains over time, comparable to the variation noted between the chronologically predominant GII.4 strains GII.4-2006b
and GII.4-2009. Our data suggest that in some individuals the evolution that occurs during a chronic norovirus infection over-
laps with changing antigenic epitopes that are associated with successive outbreak strains and may select for isolates that are po-
tentially able to escape herd immunity from earlier isolates.
IMPORTANCE
Noroviruses are agents of gastrointestinal illness, infecting an estimated 21 million people per year in the United States alone. In
healthy individuals, symptomatic infection typically resolves within 24 to 48 h. However, symptoms may persist for years in im-
munocompromised individuals, and development of successful treatments for these patients is a continuing challenge. This
work is relevant to the design of successful norovirus therapeutics for chronically infected patients; provides support for previ-
ous assertions that chronically infected individuals may serve as reservoirs for new, antigenically unique emergent strains; and
furthers our understanding of genogroup II, genotype 4 (GII.4) norovirus immune-driven molecular evolution.
Noroviruses are the leading cause of gastrointestinal illnessworldwide. While typically an acute disease, norovirus in-
fections can be serious in the young, old, and immunocompro-
mised, as these groups are at risk for more severe disease and
death (1–3). Norovirus is spread rapidly in environments
where people are found in close proximity, including schools
and daycare centers, nursing homes, cruise ships, and hospi-
tals. Importantly, hospital outbreaks can result in significant
economic damage, with direct and indirect costs from a single
outbreak reaching $650,000 (4).
Noroviruses are members of the family Caliciviridae and con-
tain an 7.5-kb single-stranded, positive-polarity RNA genome.
They are divided into 5 genogroups; genogroups I and II are re-
sponsible for the majority of human disease and are further sub-
divided into at least 9 and 22 genotypes, respectively (5). The
human norovirus genome contains three open reading frames
(ORFs) encoding the nonstructural proteins, the ORF2 major
capsid protein (VP1), and the ORF3 minor capsid protein (VP2)
(6). VP1 is further divided into the shell (S) and protruding (P)
domains, with the P domain comprised of the P1 and P2 sub-
domains (6). Phylogenetic studies indicate that the P2 subdomain
is the most variable region of the norovirus genome (7, 8). The P2
subdomain is also the most surface-exposed region of the norovi-
rus capsid, interacting with antibodies and histo-blood group an-
tigens (HBGAs), which serve as binding ligands and putative re-
ceptors for human norovirus docking and entry.
Genogroup II, genotype 4 (GII.4) strains cause over 70% of all
norovirus outbreaks (9), and epidemic outbreaks occur every 2 to
4 years, involving new antigenically distinct strains (7, 10). Studies
of antigenic variation in GII.4 norovirus have shown that the P2
region is involved in strain-specific antibody recognition (7, 11,
12) and contains at least three blockade (potential neutralization)
epitopes (13–15). In epidemic strains, genetic variation in P2 is
linked to antigenic changes over time, indicating that molecular
evolution in the P2 subdomain is likely driven by escape from
human herd immunity (12–17).
Noroviruses typically cause acute infection in healthy individ-
uals, resulting in symptomatic infection for 24 to 48 h, followed by
virus shedding for 2 to 4 weeks (18, 19). However, some immu-
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nocompromised individuals, such as transplant patients on im-
munosuppressive drugs, those with primary immunodeficiencies,
cancer patients undergoing chemotherapy, and those with HIV
infections, may develop chronic norovirus infection. Symptom-
atic infection and virus shedding in these patients can persist for
weeks to years (20–25) and can result in medical issues, such as
dehydration and nutrient deficiencies (26), making development
of treatment options for these patients an important priority. Un-
fortunately, there are no approved therapeutics or vaccines for
controlling norovirus infections. Attempted methods to control
chronic infection have included treatment with drugs effective
against other diarrheal diseases (27), adjustment of the immuno-
suppressive drug type or dosage (28), and oral or enteral admin-
istration of human IgG (29–32). Although reduction in immuno-
suppression coupled with IgG administration has shown promise
for some transplant patients, IgG therapy has failed in other stud-
ies, and reduction of immunosuppression is not always possible.
Existing studies provide a basis to investigate important ques-
tions about chronic norovirus infection. Although unconfirmed,
one recent hypothesis is that chronically infected norovirus pa-
tients may be important sources of infection, both in health care
settings (33) and as potential reservoirs for new, emergent GII.4
norovirus strains (20, 23, 25). Although the fitness and the infec-
tivity of chronically shed virus are currently unknown, potential
accounts of chronic norovirus shedders involved in hospital out-
breaks and transmission of virus to both immunocompromised
and immunocompetent individuals have been documented (21,
33, 34).
The virus capsid sequence and phylogenetic data from chron-
ically infected patients have shown substantial genetic variation
over the course of infection in many, but not all, patients (22, 23,
35). Siebenga et al. found that the capsid mutation rate was linked
to immune impairment, suggesting that immune-driven selection
drives evolution in the capsid during chronic infection (35) and
explains differences in evolution, depending on the level of immu-
nosuppression. Additional studies have corroborated a role for
intrahost immune-driven selection by demonstrating that virus
isolated from chronically infected patients undergoes positive se-
lection and exhibits higher genetic diversity in the capsid protein
than virus from acutely infected individuals (23, 25). In some
chronically infected patients with GII.4 strain infections, many of
the changes occur in blockade epitopes, areas of known or pre-
dicted antigenic importance, but antigenic comparisons have not
been performed (13–15, 22, 35).
Here, we compare and contrast the antigenic differences using
a panel of polyclonal and monoclonal antibodies and time-or-
dered virus-like particles (VLPs) derived from early (day 1 [P.D1])
and late (day 302 [P.D302]) capsid protein amino acid sequences
from a chronically infected immunocompromised patient (23).
Our data demonstrate significant antigenic differences between
intrahost variants that mirror the degree of variation seen in major
successive norovirus strains, suggesting that chronic norovirus in-
fections can evolve antigenically unique variants with the poten-
tial to seed future norovirus outbreaks.
MATERIALS AND METHODS
Sequences and structural-homology models. The GenBank (NCBI se-
quence database) sequences used in this study were JQ478409.1 (GII.4-
2006b) (15), JQ417309 (P_04.2009, or P.D1) (23), JQ417327 (P_02.2010,
or P.D302) (23), JN595867.1 (GII.4-2009) (15), and JX459908.1 (GII.4-
2012) (36), and the VA387 crystal structure is available from the RCSB
Protein Data Bank, identifier 2OBT (37). We refer to the sequences orig-
inally named P_04.2009 and P_02.2010 as P.D1 and P.D302, respectively,
for simplicity here. Homology models of these sequences were con-
structed using Modeler (Max-Planck Institute for Developmental Biol-
ogy) and modeled in PyMOL.
Production of VRPs. Virus replicon particles (VRPs) carrying the
norovirus major capsid gene were produced as previously described (38).
Briefly, expression vector pVR21 carries the Venezuelan equine encepha-
lomyelitis (VEE) genome with the VEE structural genes replaced with a
commercially synthesized norovirus ORF2 gene (BioBasic) behind the
26S promoter. The VEE norovirus ORF2 construct and two separate plas-
mids expressing either the VEE 3526 E1 and E2 glycoproteins or the VEE
3526 capsid protein were used to make RNA. RNA from all three con-
structs was electroporated into BHK cells, and 48 h later, VRPs were har-
vested and purified by high-speed centrifugation. VRP titers were deter-
mined by counting fluorescent cells detected with fluorescein
isothiocyanate (FITC)-labeled antibody. Virus-like particle (VLP) pro-
duction from VRPs and structural integrity were confirmed by electron
microscopy (EM).
Production of VLPs. VLPs were produced as previously described (13,
15). Briefly, commercially synthesized norovirus ORF2 (BioBasic) from a
chronically infected patient sequence or outbreak strain sequence was
cloned into expression vector pVR21 behind the 26S promoter, and ge-
nome length RNAs were synthesized in vitro using T7 RNA polymerase.
RNA from the VEE ORF2 construct and helper RNAs was electroporated
into BHK cells, and 24 h later, VLPs were harvested and purified by high-
speed centrifugation. The VLP concentration was determined by bicin-
choninic acid (BCA) protein assay (Pierce), and structural integrity was
confirmed for all VLPs by EM.
HBGA binding assay. HBGA assays were performed as previously
described (7). Briefly, avidin-coated plates (Pierce) were coated with 10
g/ml synthetic biotinylated HBGAs (GlycoTech), followed by addition
of 2 g/ml VLPs. HBGA binding was detected with strain-specific mouse
polyclonal sera, followed by anti-mouse IgG-horseradish peroxidase
(HRP) (GE Healthcare) and then One-Step Ultra TMB HRP substrate.
Positive reactivity for each HBGA was defined as an optical density at 450
nm (OD450) signal above or equal to 3 times the background binding
(background range, 0.049 to 0.066) after background subtraction.
EIAs. Reactivity with mouse and human monoclonal antibodies
(MAbs) was determined by enzyme-linked immunoassay (EIA). Plates
were coated with 0.5 g/ml VLPs in phosphate-buffered saline (PBS), and
then 2-fold serial dilutions of the MAb starting at 1 g/ml MAb were
added. Anti-mouse or -human IgG-HRP (GE Healthcare), followed by
One-Step Ultra TMB EIA HRP substrate solution, was used for detection.
Positive reactivity was defined as a mean OD450 of 0.2 after background
subtraction. The data represent a combination of three independent trials,
with each VLP run in duplicate in each trial. Sigmoidal dose-response
analysis was performed as previously described (14) using the reactivity at
1 g/ml as 100% binding. Fifty percent effective concentrations (EC50s)
among VLPs were compared using one-way analysis of variance
(ANOVA) with Dunnett’s posttest. A P value of 0.05 was considered
significant. VLPs with maximum reactivity below a mean OD450 of 0.2
were assigned a value of zero for graphical representations.
VLP-carbohydrate ligand-binding antibody blockade assays. Block-
ade assays using pig gastric mucin (PGM) type III (Sigma Chemicals) were
performed as previously described (14). PGM-bound VLPs were detected
by rabbit anti-GII.4 norovirus polyclonal sera. The percent control bind-
ing was defined as the VLP ligand-binding level in the presence of test
antibody or sera compared to the binding level in the absence of antibody
multiplied by 100. All MAbs and sera were tested for blockade potential at
2-fold serial dilutions ranging from 0.0039 to 2 g/ml (mouse MAbs),
0.0039 to 16 g/ml (human MAbs), and 0.0098 to 5% (mouse sera). The
data from blockade experiments using monoclonal antibodies represent a
combination of three independent trials, with each VLP run in duplicate
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in each trial. The data from blockade experiments using polyclonal mouse
sera represent a combination of two independent trials in which sera from
five individual mice were tested for each VLP. Sigmoidal dose-response
analysis was performed as previously described, and EC50s among VLPs
were compared using one-way ANOVA with a Bonferroni posttest. A P
value of 0.05 was considered significant. Blockade assays utilize VLP
concentrations in the low nanomolar range; therefore, the assay does not
discriminate between antibodies with subnanomolar affinities.
Monoclonal antibodies and mouse polyclonal sera. Mouse (12) and
human (14) monoclonal antibodies were isolated as previously described.
BALB/c mice (five per group) were immunized by footpad injection with
5  104 VRPs expressing the norovirus capsid gene (GII.4-1987, GII.4-
2002, GII.4-2006b, GII.4-2009, P.D1, or P.D302). Mice were boosted on
day 21 and euthanized 7 days postboost, and sera were harvested. All
animal studies were approved and conducted under the guidelines of
UNC Chapel Hill’s Institutional Animal Care and Use Committee (web
ID 23433).
Antigenic cartography. We utilized multidimensional-scaling (MDS)
approaches as described and implemented within the AntigenMap 3D
software (39, 40). The EC50 blockade titers of various sera against a panel
of VLPs were normalized to the maximum blockade titer of each serum, as
well as to the maximum overall blockade titer across sera (normalization
method 1 in AntigenMap 3D). The normalized values were used to calcu-
late Euclidean distances (D) between each pair of VLPs. For greater ana-
lytical, visualization, and graphical purposes, we then utilized the Mat-
lab8.1 (MathWorks Inc., Natick, MA) cmdscale function to determine the
XYZ coordinates so that the data could be displayed in 3 dimensions while
maintaining the underlying Euclidean distances directly calculated from
the data. We utilized R (www.r-project.org), with the package rgl for
three-dimensional (3D) visualization of these data. We confirmed the
output of our pipeline with that produced by AntigenMap 3D.
RESULTS
Comparison of sequence changes among chronic-infection iso-
lates and GII.4-2006b. Previous work had shown that changes
identified in a few key surface-exposed epitopes correlate with
shifts in GII.4 norovirus antigenicity (11, 13–15), including resi-
dues in epitope A (294, 296 to 298, 368, and 372) (13), epitope D
(393 to 395) (14), and epitope E (407, 412, and 413) (15). Changes
in these residues likely alter the ability of preexisting immunity to
neutralize the virus, selecting for the emergence of new epidemic
strains.
To study the within-host antigenic evolution of noroviruses
during a chronic human infection, we aligned the sequences of the
capsid P2 domains of GII.4-2006b, P.D1, and P.D302 to examine
sequential amino acid changes from GII.4-2006b through P.D302
after at least 10 months of within-host evolution (23). Note that
day 1 and day 302 refer to the days of sample collection and not
from the beginning of infection, as the time between the beginning
of infection and the collection of the day 1 sample is unknown.
Between VP1 amino acid positions 248 and 434, there are 9 differ-
ences between GII.4-2006b and P.D1. After 10 months, there were
15 additional differences between P.D1 and P.D302 and 20 differ-
ences between GII.4-2006b and P.D302 located between these
amino acid positions (Fig. 1A). Similarly, there are 16 differences
spanning this domain between GII.4-2006b and subsequent epi-
demic strains, GII.4-2009 and GII.4-2012. Two of the differences
between GII.4-2006b and P.D1 (S368A and S393G) and four of
the differences between GII.4-2006b and P.D302 (A294G, S296T,
S368A, and N412D) are located within blockade epitope sites (Fig.
1B). Four differences in blockade epitope residues also exist be-
tween P.D1 and P.D302 (A294G, S296T, G393S, and N412D) (Fig.
1B). We synthesized GII.4-2006b, P.D1, and P.D302 genes; ex-
pressed VLPs representing these strains; and measured differences
in antigenicity and HBGA binding among the chronic-infection
isolates and GII.4-2006b using biological assays. In addition, sev-
FIG 1 Sequence changes in chronically infected patient strains compared to GII.4-2006b. (A) Available capsid amino acid sequences for GII.4-2006b, P.D1, and
P.D302 were aligned using Clustal Omega, and sequence differences among GII.4-2006, P.D1, and P.D302 are shown. GII.4-2006b residues are shown in purple.
P.D1 and P.D302 differences from GII.4-2006b are indicated in light blue, while orange indicates reversion to the GII.4-2006b residues. (B) Alignment of
GII.4-2006b, P.D1, and P.D302 amino acid sequences in and around epitopes A, D, and E. Green indicates a position within a defined epitope, while white
indicates nearby residues that may impact antigenicity in these epitopes. Yellow indicates an amino acid position newly defined as part of epitope A. (C) Structural
homology models of GII.4-2006b, P.D1, and P.D302 capsid P2 dimers shown from a top view. Purple shows the locations of epitopes A, D, and E on the capsid
P2 dimer, while green shows changed amino acid residues in P.D1 and P.D302 compared to GII.4-2006b.
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eral amino acid substitutions present in the chronic-infection
strains that are conserved in past epidemic strains may also influ-
ence the antigenic and HBGA binding characteristics of epitope
sites A (292, 295, and 373), D (391), and E (414) (Fig. 1B) based on
their positions relative to these epitopes in GII.4 homology mod-
els (Fig. 1C).
Comparison of HBGA binding in chronic-infection isolates
to that in GII.4-2006b. To evaluate differences in HBGA binding
preferences among GII.4-2006b, P.D1, and P.D302, we measured
VLP binding to synthetic biotinylated carbohydrates (A, B, Lea,
Leb, Lex, Ley, H type 1, and H type 3). As previously reported,
GII.4-2006b bound A, B, Leb, Ley, and H type 3 (41). In contrast,
chronic-infection strain VLPs exhibited HBGA binding profiles
different from those of GII.4-2006b and from each other (Table
1). P.D1 was able to bind A, B, and H type 3, while P.D302 bound
only B and H type 3 synthetic biotinylated HBGAs. This indicates
that HBGA binding preferences may be altered over time during
chronic infection, perhaps influenced by individual within-host
HBGA expression phenotypes.
Reactivity with GII.4 mouse and human MAbs. To measure
antigenic differences among VLPs representing GII.4-2006b and
chronic strains P.D1 and P.D302, we performed EIAs using mouse
and human MAbs. We tested five GII.4-2006b mouse MAbs (G2,
G3, G4, G6, and G7) and two GII.4 human MAbs (NVB111 and
NVB43.9), all of which target epitope site A residues (294, 296 to
298, 368, and 372), for EIA binding with GII.4-2006b, P.D1, and
P.D302 VLPs. GII.4-2006b and P.D1 differ in one epitope site A
position, where P.D1 contains S368A compared to GII.4-2006b.
P.D302 is different from GII.4-2006b at 3 of 6 epitope site A resi-
dues—A294G, S296T, and S368A—while P.D1 and P.D302 are
different at 2 of 6 epitope site A residues—A294G and S296T. We
also tested the reactivities of these VLPs with one human MAb
(NVB97), which targets epitope site D residues (393 to 395).
While GII.4-2006b and P.D302 share identical epitope site D res-
idues, P.D1 has an S393G change compared to GII.4-2006b. In
addition, we tested one human MAb (NVB71.4) that targets an
unmapped conserved GII.4 epitope (14). Consistent with previ-
ously reported results, all the MAbs reacted strongly with GII.4-
2006b VLPs (12, 14) (Table 2). In contrast, EC50s for P.D1 VLPs
were significantly different (P  0.05) from those for GII.4-2006b
VLPs for mouse MAbs G2, G4, and G6 and human MAbs
NVB43.9 and NVB111 (Table 2). Moreover, EC50s for P.D302
VLPs were significantly different from those for GII.4-2006b VLPs
for all MAbs except NVB71.4 and different from those for P.D1
VLPs for all but NVB71.4 and NVB111 (Table 2). This indicates
that epitope sites A and D are antigenically distinct among GII.4-
2006b, P.D1, and P.D302, demonstrating antigenic variation over
the course of chronic infection in important blockade epitopes.
Blockade activities for GII.4 mouse and human MAbs. Com-
pared to EIA, neutralization is a more relevant measure of func-
tional antigenic change. To test the potential neutralization activ-
ities of MAbs (GII.4-2006b G2, G3, G4, G6, and G7 and NVB43.9,
NVB71.4, NVB97, and NVB111) against GII.4-2006b, P.D1, and
P.D302 VLPs, we performed blockade assays, a correlate of pro-
tective immunity (42) and a neutralization surrogate. Consistent
with previous findings, all the MAbs were able to block ligand-
TABLE 1 Chronic-infection strain HBGA binding preferences
Strain
Bindinga
A B Lea Leb Lex Ley H type 1 H type 3
GII.4–2006        
P.D1        
P.D302        
a VLPs representing GII.4-2006b, P.D1, and P.D302 were assayed for the ability to bind
synthetic biotinylated HBGAs A, B, Lea, Leb, Lex, Ley, H type 1, and H type 3 by
carbohydrate binding assay. Positive reactivity () was defined as a value greater than
or equal to 3 times the background binding value.
TABLE 2 GII.4 mouse and human MAb EIA reactivities with chronic-infection strains
Mouse and human GII.4 monoclonal antibodies were assayed for reactivity with GII.4-2006b, P.D1, and P.D302 VLPs by
multiple-dilution EIA. The mean percent binding (the percentage of the VLP bound to antibody in the dilution course
compared to the amount of VLP bound with antibody at 1 g/ml) of each VLP was fitted with a sigmoidal curve, and the mean
EC50 (g/ml) EIA reactivity titers for GII.4-2006b, P.D1, and P.D302 were calculated. Mean EC50 EIA reactivity titers for the test
VLP that were significantly different from the mean EC50 for GII.4-2006b (light gray) (*) or were significantly different from
both GII.4-2006b and P.D1 (P  0.05) (dark gray) (**) are indicated. Monoclonal antibodies that did not demonstrate EIA
reactivity at or above an OD450 of 0.2 at 1 g/ml with a particular VLP are denoted by an EC50 of 1 g/ml. The statistics were
calculated by one-way ANOVA with a Bonferroni posttest.
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VLP interactions for GII.4-2006b (12, 14) (Fig. 2). Likewise, P.D1
was blocked by all the MAbs (Fig. 2). However, EC50 blockade
titers for two out of five GII.4-2006b mouse MAbs, G2 (Fig. 2A)
and G7 (Fig. 2E), and two of four GII.4 human MAbs, NVB111
(Fig. 2G) and NVB71.4 (Fig. 2I), were significantly different, re-
quiring 7.1 times, 2 times, 2 times, and 3.2 times more antibody,
respectively, for blockade than GII.4-2006b VLPs. P.D302 VLP-
ligand binding was blocked by GII.4-2006b mouse MAbs G2 (Fig.
2A), G6 (Fig. 2D), and G7 (Fig. 2E), but not by G3 (Fig. 2B) or G4
(Fig. 2C), and blocked by GII.4 human MAb NVB71.4 (Fig. 2I),
but not by NVB43.9 (Fig. 2F), NVB111 (Fig. 2G), or NVB97 (Fig.
2H). EC50 blockade titers were significantly different between
GII.4-2006b and P.D302 for G2, G6, G7, and NVB71.4, requiring
12.6 times, 15.9 times, 12 times, and 6.8 times more MAb than for
GII.4-2006b, respectively. Overall, EC50 blockade titers were sig-
nificantly higher for P.D302 than for both GII.4-2006 and P.D1
for all tested MAbs, demonstrating major antigenic changes in
epitope sites A and D over the course of chronic norovirus infec-
tion.
Blockade responses of strain-specific mouse polyclonal sera.
While monoclonal antibodies are informative about the changes
in a single epitope, polyclonal sera are needed to evaluate global
antigenic changes. To measure differences in the total antibody
response, we immunized mice with VRPs expressing the capsid
FIG 2 GII.4 mouse and human MAb blockade responses against chronic-infection strains. (A to I) Mouse and human GII.4 monoclonal antibodies were assayed
for the ability to block GII.4-2006b, P.D1, and P.D302 VLP interaction with carbohydrate ligand. The mean percent control binding (the percentage of the VLP
bound to carbohydrate ligand in the presence of an antibody compared to the amount of VLP bound with no antibody present) of each VLP was fitted with a
sigmoidal curve, and the mean EC50 (g/ml) blockade titers for GII.4-2006b, P.D1, and P.D302 were calculated. The error bars represent 95% confidence
intervals. The asterisks indicate that the mean EC50 blockade titer for the test VLP was significantly different from the mean EC50 for GII.4-2006b (P  0.05) (*)
or was significantly different from those of both GII.4-2006b and P.D1 (P  0.05) (**). Monoclonal antibodies that did not block a particular VLP were assigned
an EC50 of 2 times the upper limit of detection for statistical analysis and are shown on the graph as data points above the upper limit of detection (dashed lines).
Statistics were calculated by one-way ANOVA with a Bonferroni posttest.
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genes from GII.4-2006b, P.D1, and P.D302 or GII.4-2009, the
consecutive outbreak strain following GII.4-2006, and measured
the induced serum blockade responses (Fig. 3). Mice immunized
with GII.4-2006b VRPs mounted a robust blockade response
against homotypic GII.4-2006b VLPs, while significantly more se-
rum was needed to block GII.4-2009, P.D1, and P.D302 VLPs (16
times, 9.4 times, and 12.7 times, respectively) (Fig. 3A). Sera from
mice immunized with GII.4-2009 VRPs induced a strong block-
ade response against GII.4-2009 VLPs; however, significantly
more serum was needed to block GII.4-2006b and P.D302 VLPs,
with 39 times more serum needed to block P.D302 VLPs than
GII.4-2009 (Fig. 3B). Sera from mice immunized with P.D1 VRPs
most efficiently blocked homotypic P.D1 VLPs. The EC50s indi-
cated that more serum is required to block GII.4-2009 (3 times)
and P.D302 (25.8 times) than P.D1, while GII.4-2006b and P.D1
EC50 titers were not significantly different (Fig. 3C). Sera from
mice immunized with P.D302 VRPs efficiently blocked P.D302
VLP-ligand interactions and weakly blocked GII.4-2006b and
P.D1, requiring 92 times and 61 times more serum, respectively.
P.D302 serum was unable to block GII.4-2009 VLPs (Fig. 3D).
These data show that chronic-isolate VLPs induce antibody re-
sponses that are different from those of the parental strain and
each other, demonstrating major changes in total antibody re-
sponse over the course of chronic infection.
Antigenic cartography. In order to further describe and visu-
alize the differences between the antigenic properties of virus
strains, we utilized the MDS approach known as antigenic cartog-
raphy (39, 40). Specifically, we used the pipeline described in
AntigenMap 3D (39) to measure and visualize the antigenic rela-
tionships among outbreak strains GII.4-1987, GII.4-1997, GII.4-
2002, GII.4-2006b, GII.4-2009, and GII.4-2012, as well as chronic
isolates P.D1 and P.D302, explicitly contrasting antigenic rela-
tionships between naturally occurring epidemic strains, as well as
intrahost variants. The antigenic distances between strains were
measured using GII.4-1987, GII.4-2002, GII.4-2006b, GII.4-2009,
P.D1, and P.D302 mouse serum EC50 blocking titers against VLPs
representative of the specified GII.4 strains, and Euclidean dis-
tance values were calculated based on these titers (Fig. 4A). Con-
sistent with earlier findings (12), early (GII.4-1987, GII.4-1997,
and GII.4-2002) and late (GII.4-2006b, GII.4-2009, and GII.4-
2012) strains formed distinct clusters (Fig. 4B and C). Not surpris-
ingly, the early within-host variant, P.D1, grouped closely with
late strains (Fig. 4B and C), reflecting its origins from the GII.4-
2006b lineage. In contrast, P.D302 did not group with any other
strain and was antigenically distant from both the early and con-
temporary isolates. In order to confirm the visual analysis of these
antigenic similarities, we compared Euclidean distances (D) be-
tween each pair of VLPs across all sera utilized for antigenic car-
FIG 3 Blockade activity of mouse polyclonal sera against homotypic and heterotypic VLPs. Mice were immunized with VRPs expressing the capsid genes of
GII.4-2006b, GII.4-2009, P.D1, and P.D302, and sera collected from the mice were tested for blockade activity against GII.4-2006b, GII.4-2009, P.D1, and P.D302
VLPs. Shown is the blockade activity of sera from mice immunized against GII.4-2006b (A), GII.4-2009 (B), P.D1 (C), and P.D302 (D) with homotypic and
heterotypic VLPs. The mean percent control binding (the percentage of the VLP bound to carbohydrate ligand in the presence of sera compared to the amount
of VLP bound with no serum present) of each VLP was fitted with a sigmoidal curve, and the mean EC50 (% sera) blockade titers for GII.4-2006b, GII.4-2009,
P.D1, and P.D302 were calculated. The error bars represent 95% confidence intervals. *, the mean EC50 blockade titer for the test VLP was significantly different
from the mean EC50 for the homotypic strain (P  0.05). Sera that did not block a particular VLP were assigned an EC50 of 10% sera for statistical analysis and
are shown on the graph as data points above the upper limit of detection (dashed lines). Statistics were calculated by one-way ANOVA with a Bonferroni posttest.
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tography (the Euclidean distance measures the straight-line dis-
tance between two points in a multidimensional space). We first
examined the groupings of early and late GII.4 outbreak strains.
The average distance within a group was 3.79 (range, 2.11 to 6.39),
while the average distance between early and contemporary clus-
ters was 10.7 (range, 8.49 to 13.32), with each distance unit corre-
sponding to a roughly 1.25-fold difference in blockade response
between viruses (Fig. 4A). As shown in Fig. 4B and C, P.D1
grouped closely with late outbreak strain VLPs, with an average D
value of 3.46 (range, 2.26 to 5.09) (Fig. 4A). In contrast, P.D302
was quite distinct from both early and late outbreak strain viruses,
as well as from P.D1, with an average D value of 9.92 (range, 8.73
to 11.62) (Fig. 4A). During an 10-month chronic infection in
this individual, our data demonstrate that intrahost evolution can
generate novel variants with unique HBGA binding patterns and
encoding unique antigenic differences that are as dramatically dis-
tinct as those of time-ordered, epidemic outbreak strains that
emerge in human populations.
Expansion of epitope site A. We next determined whether
novel sites of within-host evolution can refine existing epitope
maps and identify potential immunogenic changes in epidemic
strains of the future. Amino acid position 373 exhibited an N373H
change between P.D1 and P.D302 but was conserved in major
GII.4 epidemic strains until an N373R substitution emerged in
GII.4-2012 Sydney. Although not supported with empirical data,
recent work by Allen et al. (43) suggests that this change in the
Sydney strain may have impacted its emergence. Since changes to
residue 373 have never been shown to influence immunogenicity,
and it is not included as a diagnostic A epitope site residue, this
potentially hampers new epidemic strain identification. To deter-
mine whether position 373 contributes to antigenic differences in
epitope A, we used the blockade assay to test potential neutraliza-
FIG 4 Antigenic cartography for GII.4 noroviruses. MDS was used to identify the antigenic relationships between different norovirus strains. (A) Euclidean
antigenic distances between virus strains were calculated based on the EC50 efficacies of antisera raised against GII.4-1987, GII.4-2002, GII.4-2006b, GII.4-2009,
P.D1, and P.D302 VLPs. The green squares represent distances within either the early (1987, 1998, and 2002) or late (2006, 2009, and 2012) virus groups. The
purple squares show the distances between early and late virus groups. (B and C) We determined XYZ coordinates that maintain the underlying Euclidean
distances between viruses while illustrating the relationships between GII.4 norovirus strains, with each map distance roughly corresponding to an 1.25-fold
change in blockade response. (B) Early strains GII.4-1987 (yellow), GII.4-1997 (red), and GII.4-2002 (light blue) grouped together (lower right), and the late
strains GII.4-2006b (light purple), GII.4-2009 (dark blue), and GII.4-2012 (dark purple) grouped together (lower left). P.D1 grouped with late strains, closest to
GII.4-2006b, while P.D302 was separate from either late or early strains (top). (C) Side view of the same 3D graph as in panel B, showing the antigenic differences
between strains.
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tion of VLPs representing the parental strains GII.4-2009 New
Orleans and GII.4-2012 Sydney and chimeric sequences GII.4-
2012.09A, GII.4-2012.09A.R373N, and GII.4-2012.R373N (Fig. 5)
by epitope A targeting human MAb 43.9. GII.4-2009 was effi-
ciently blocked by MAb 43.9, while GII.4-2012 required signifi-
cantly more (55.3 times) MAb for blockade. Blockade response
was partially restored in chimeras GII.4-2012.09A and GII.4-
2012.R373N but required 1.5 times and 4.8 times more MAb,
respectively, for blockade than GII.4-2009. EC50 blockade titers
were not statistically different between GII.4-2012.09A.R373N
and GII.4-2009 VLPs. Similar trends were seen using mouse MAbs
targeting epitope A residues (data not shown).
DISCUSSION
Noroviruses are an important cause of gastroenteritis in immuno-
compromised individuals (44, 45), who are at increased risk for
severe disease outcomes (1, 44). Recent vaccine trials utilizing a
VLP-based vaccine approach support the idea that efficacious vac-
cines that elicit short-term protection in some healthy individuals
can be generated, but vaccines may not protect immunocompro-
mised populations, making development of therapeutics that ef-
fectively treat or prevent norovirus infections a top health priority.
In immunocompetent people, norovirus infection results in
acute disease outcomes (46). In contrast, immunocompromised
individuals can develop symptomatic disease and high-titer virus
shedding for up to years. Unfortunately, the literature on specific
chronically infected norovirus patient populations is sparse, and
the duration and severity of chronic norovirus infections are likely
influenced by several factors, including the underlying condition,
drug treatment regime, degree of immunosuppression, and rate of
within-host virus evolution, making it difficult to define the char-
acteristics of a typical chronic norovirus case. From these limited
studies, it is difficult to discern whether there are characteristics of
chronic norovirus infection that are broadly applicable to all pop-
ulations and characteristics that are true to specific populations,
or whether characteristics vary by each individual case. Previous
work has shown that during the course of chronic infection, virus
genetic diversity can expand quickly (22, 23, 25, 35); however, it
was previously unknown whether this genetic variation translated
into antigenic variation or the emergence of antigenically unique
isolates that differ significantly from contemporary epidemic
strains. For the first time, our work clearly demonstrates the po-
tential for significant antigenic variation over the course of
chronic infection within an individual, which is important in
terms of therapeutic treatment considerations and for studying
the potential role of chronic shedders as reservoirs for evolving
new outbreak strains.
Since there is no known animal reservoir for human norovi-
ruses (47), the available data indicate that new GII.4 strains likely
arise naturally within the human population by epochal evolu-
tion, immune-driven selection, and interhost transmission over
time (12–14, 16, 17). The occurrence of frequent long-term
chronic infections in immunosuppressed patients also represents
a possible source of new GII.4 norovirus strains with epidemic
potential (23, 25, 35), as these patients may provide an appropri-
ate environment for sustained immune-directed molecular evo-
lution by targeting previously identified surface-exposed blockade
epitopes for mutation-driven escape. Evidence supporting this
hypothesis includes sequence data from chronically infected pa-
tients that demonstrate the emergence of genetic changes in GII.4
blockade epitopes that modulate interhost antigenicity (22, 35).
This diverse pool may contain variants antigenically distinct from
the predominant circulating strain, allowing the emergence of a
new strain under the right conditions (25). However, host and
environmental factors, coupled with the type and degree of im-
munosuppression, may affect the rate and complexity of intrahost
evolution that occurs over time (23), and future work that evalu-
ates the roles of different immunosuppressive conditions in intra-
host norovirus evolution is needed.
Our work demonstrated intrahost antigenic changes within
epitope site A (amino acids 294, 296 to 298, 368, and 372). Inter-
estingly, P.D302 contained residue substitutions in amino acid
positions 292, 295, and 373, which are conserved in major GII.4
outbreak strains, except for 373, which was altered in the most
recent predominant strain, GII.4-2012 Sydney. Changes in these
residues likely impact epitope A antibody binding and blockade
response, either by altering the conformational landscape of the
epitope or by directly inhibiting the interaction of the antibody
with the capsid. Using GII.4-2009/GII.4-2012 chimeric VLPs, we
demonstrated that residues at position 373 impact the blockade
response of human MAb NVB43.9, an antibody that targets
epitope A. This demonstrates that position 373 is part of epitope
A, expanding the epitope to 7 positions. Furthermore, we suggest
that monitoring intrahost-evolved strains may provide a novel
diagnostic strategy to map key residues capable of mediating an-
tigenic changes in future outbreaks. While positions 292 and 295
have been conserved in previous predominant circulating GII.4
strains, their ability to change in this patient and their proximity to
known epitope A residues suggest that these residues could poten-
tially impact antigenic change in epitope A in future epidemics, as
residue 373 did in GII.4-2012 Sydney.
FIG 5 Expansion of epitope site A. Epitope A targeting human GII.4 MAb
43.9 was assayed for its ability to block GII.4-2009 New Orleans, GII.4-2012
Sydney, GII.4-2012.09A, GII.4-2012.R373N, and GII.4-2012.09A.R373N VLP
interaction with carbohydrate ligand. The mean percent control binding (the
percentage of the VLP bound to carbohydrate ligand in the presence of an
antibody compared to the amount of VLP bound with no antibody present) of
each VLP was fitted with a sigmoidal curve, and the mean EC50 (g/ml) block-
ade titers for all VLPs were calculated. The error bars represent 95% confidence
intervals. Statistics were calculated by one-way ANOVA with Dunnett’s post-
test. *, the mean EC50 blockade titer was significantly different from that of
GII.4-2009.
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Reactivity and blockade response data for antibody NVB97
demonstrate antigenic evolution in epitope site D during chronic
infection. Epitope site D minimally includes residues 393 to 395
and is in close proximity to the carbohydrate binding pocket (37),
and previous work demonstrated that modulation of residues
within the epitope modulates HBGA specificity (7). Evolution in
this epitope site is likely driven both by antibody selective pressure
and pressure to maintain binding to one or more HBGAs. Despite
conservation of residues 393 to 395 between GII.4-2006b and
P.D302, antigenic phenotypes differ significantly, demonstrating
that NVB97 recognition is modulated by amino acid positions
outside the previously defined epitope site D residues. Position
391, which is close to the carbohydrate binding pocket, is con-
served in major outbreak strains and between GII.4-2006b and
P.D1, and previous work demonstrated that an alanine substitu-
tion at this residue had little impact on HBGA binding (48). Nei-
ther the antigenic consequences of residue changes nor the im-
pacts of other residue substitutions on HBGA binding at this
position have been rigorously evaluated, meaning that the D391N
change in P.D302 may contribute to both the HBGA reactivity and
antibody blockade differences observed for P.D302. To explore
this possibility, we created homology models of these P2 domains
and compared the predicted polar interactions present in residues
390 to 395 (Fig. 6) among GII.4-2006b, P.D1, and P.D302.
Conformational comparisons between GII.4-2006b and P.D1
show general similarities in the shapes created by residues 390 to
395, with exceptions being the loss of a side chain in 393 of P.D1
and slight shifts in position for side chains in residues 394 and 395
(Fig. 6A and B). These conformational changes appear to impact
the polar interactions within these residues, as the loss of the side
chain in residue 393 ablates the hydrogen bond present in GII.4-
2006b. In addition, the positional shifts in residues 394 and 395 in
P.D1 appear to prevent the formation of another hydrogen bond
present in GII.4-2006b. Conformational comparisons between
GII.4-2006b and P.D302 demonstrate that the residue change at
391 has a significant impact on the shape and hydrogen-bonding
networks for residues 390 to 395 (Fig. 6A and C). In P.D302,
position 391 is bent downward, which differs from the position of
the amino acid in GII.4-2006b and P.D1. The result of this change
is the formation of a hydrogen bond between the side chain and
the main chain of 391. In addition, though residue 393 is con-
served between GII.4-2006b and P.D302, the side chain is shifted
downward in P.D302 compared to GII.4-2006b, shifting the po-
sition of the hydrogen bond found at this residue. The formation
of two additional novel hydrogen bonds between 390 and 393 and
between 390 and 395 suggests that the 391 residue change and
resulting conformational changes allowed these increased polar
interactions. A slight conformational shift in residue 395 in
P.D302 appears to ablate a polar interaction found in GII.4-2006b
at this position. We also compared polar interactions of GII.4-
FIG 6 Comparison of epitope site D polar interactions among GII.4-2006 and chronic-infection strains. PyMOL was used to model the polar interactions within
residues 390 to 395 (A to C) and interactions between these residues and surrounding residues (D to F). GII.4-2006b is shown in purple (A and D), P.D1 is shown
in teal (B and E), and P.D302 is shown in pink (C and F). Residues 390 to 395 are shown in orange for GII.4-2006b, yellow for P.D1, and aqua for P.D302. The
dotted lines represent structure-based predicted polar interactions. (D to F) The dark-purple residues represent positions that interact with HBGAs.
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2006, P.D1, and P.D302 to residues outside 390 to 395 (Fig. 6D to
F). GII.4-2006b and P.D1 displayed five conserved polar interac-
tions with surrounding amino acids (Fig. 6D and E), while P.D302
lost the polar interaction at residue 391 and gained an additional
bond at residue 394 (Fig. 6F).
In addition to epitope site D being an antibody blockade
epitope, these residues modulate HBGA binding, so evolution in
this region is likely driven both by antibody selective pressure and
by pressure to maintain binding to one or more HBGAs. Interest-
ingly, all three structures maintained the two hydrogen bonds to
positions 443 and 444. Residue 443 is in the HBGA binding site
(37), and maintaining interaction with the residue may have been
selected for in this individual in order to retain HBGA binding.
The altered HBGA binding profile and reduced NBV97 binding
and blockade for P.D302 may be explained by these polar differ-
ences, although this cannot be confirmed without a crystal struc-
ture of these P2 domains bound to NVB97 and HBGAs.
Our demonstration of intrahost changes in HBGA binding
profiles in a chronically infected immunocompromised patient
suggests that selection may favor variants that bind patient-spe-
cific HBGAs. While speculative, the potential emergence of intra-
host variants that target patient-specific HBGA expression profiles
could select for the emergence of novel strains that recognize
unique or broad combinations of HBGA patterns, allowing al-
tered pathogenicity and transmission efficiencies in an individual
or across select human populations. We could not evaluate this
possibility in our study because the HBGA expression profile of
this chronically infected patient is unknown. Future research
could evaluate these HBGA phenotypic and FUT 2/3 genotypic
relationships using saliva and cells from chronically infected pa-
tients.
How much intrahost and interhost antigenic variation is nec-
essary to give rise to a new strain that could escape herd immunity
in the general population? Using blockade EC50 data from mouse
sera against GII.4-2006b, GII.4-2009 (representative of a succes-
sive outbreak strain), P.D1, and P.D302, we demonstrated that the
antigenic variation between P.D1 and P.D302 is 1.5 times greater
than that seen between GII.4-2006b and GII.4-2009. To further
address this question, we used antigenic cartography, which pro-
vides easily interpretable measures and visualization of multidi-
mensional antigenic relationships and has previously been used to
study antigenic differences in influenza virus strains (40, 49). This
analysis provided further support for the idea that within-host
changes in the virus can equal or exceed those differences seen
across successive outbreak strains, with the antigenic space be-
tween P.D302 and both GII.4-2006b (D 	 9.91) and P.D1 (D 	
9.15) being greater than the average between the consecutive out-
break strains used in this study (average D 	 4.98; range, 2.11 to
12.11), and mirrors the global difference between early GII.4 iso-
lates (1987, 1997, and 2002) and contemporary strains (2006b,
2009, and 2012).
Antigenic cartography is a relatively new and powerful method
with which to simply describe the multidimensional antigenic dif-
ferences between virus strains. As such, there is room for improve-
ment within these methods. Indeed, more complex statistical
models underlying antigenic-cartography approaches are being
developed to better account for uncertainty within these data sets
(49), and more comprehensive surveys of both antisera and nat-
ural GII.4 isolates over a 30-year time span will better allow the
characterization of antigenic change within noroviruses. In this
study, the use of mouse sera permitted us to use an immunologi-
cally clean background with no preexposure history and provides
a clearer starting point to evaluate specific relationships among
outbreak strains and the intrahost isolates. Future work will re-
quire well-defined, time-ordered human sera from natural epi-
demic outbreaks; time-ordered sera from intrahost chronic infec-
tions; and synthetic reconstruction of capsids representing both
outbreak and unique panels of interhost variants over time. Un-
fortunately, to date, we have been unable to obtain the samples
necessary to pursue this comprehensive investigation. Our data
suggest that intrahost evolution over a 10-month period can yield
sufficient antigenic change to escape existing herd immunity.
Clearly, additional work examining norovirus infectivity after
prolonged shedding is needed in order to clarify whether chroni-
cally infected patients are a probable source of novel epidemic
strains.
Therapeutics are needed to alleviate clinical disease during
long-term norovirus infection and to prevent the potential emer-
gence of novel antigenic variants with epidemic potential in the
general population. Some success using IgG to treat chronic no-
rovirus infection (32), coupled with our data demonstrating that
P.D1 is relatively antigenically similar to GII.4-2006b while
P.D302 is antigenically divergent, suggests that treatment early
during chronic infection may be important for virus clearance and
also supports the possibility that similarly administered, broadly
neutralizing antibodies may be viable treatment options for pa-
tients suffering from long-term norovirus infection. Our work
demonstrates that the GII.4 broadly neutralizing MAb NVB71.4
retains blockade response against P.D1 and P.D302, even though
both strains are antigenically distinct from GII.4-2006b, GII.4-
2009, and presumably other major GII.4 strains. This suggests that
NVB71.4 or other antibodies with broad cross-blockade activity
could be isolated and successfully used as norovirus therapeutics.
Importantly, different monoclonal antibodies that target other GI
and GII strain chronic infections will be needed. Furthermore,
increased surveillance of norovirus isolates from chronically in-
fected patients, as well as deep sequencing of patient isolates,
should be considered in order to better understand the transmis-
sion dynamics and genetic potential of norovirus isolates from
these patients, since they are likely different from what is seen in
the general population. Overall, our work supports the idea that
chronically infected individuals are potential reservoirs for anti-
genically novel norovirus strains, and further work to characterize
their roles in transmission and emergent norovirus outbreaks and
development of therapeutics to combat chronic infections should
be a top priority.
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